Stay updated on Pembrolizumab in Advanced Gastric Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Advanced Gastric Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Advanced Gastric Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study of pembrolizumab (MK-3475) as first-line treatment for participants with advanced gastric or gastroesophageal junction adenocarcinoma. This change may reflect new data or findings related to the efficacy or outcomes of the treatment arms in the clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:18:51.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying inclusion and exclusion criteria such as performance status, health conditions, and prior treatments. Previously, this section had no information provided.
    Difference
    29%
    Check dated 2024-05-22T20:55:20.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:32:31.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Advanced Gastric Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced Gastric Cancer Clinical Trial page.